0.554

10.34% +0.0519

After Hours: .55 -0.004 -0.72%

Purple Biotech Ltd ADR (PPBT)

Overview News Price History Option Chain Discussions Forecast Stock Split

Purple Biotech Ltd ADR stock is currently priced at $0.554, with a 24-hour trading volume of 132.25K. It has seen a +10.34% increased in the last 24 hours and a +27.56% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $0.51 pivot point. If it approaches the $0.5478 resistance level, significant changes may occur.

Previous Close:

$0.5021

Open:

$0.502

24h Volume:

132.25K

Market Cap:

$14.47M

Revenue:

Net Income/Loss:

$-19.88M

P/E Ratio:

-0.5036

EPS:

-1.1

Net Cash Flow:

$-19.93M

1W Performance:

+5.50%

1M Performance:

+27.56%

6M Performance:

-44.60%

1Y Performance:

-70.61%

1D Range:

$0.5011

$0.569

52W Range:

$0.3023

$1.98

Purple Biotech Ltd ADR Stock (PPBT) Company Profile

Name

Purple Biotech Ltd ADR

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

972 3 933 3121

Address

4 Oppenheimer Street, Science Park, Rehovot

Employee

Twitter

Next Earnings Date

2024-06-14

Latest SEC Filings

PPBT's Discussions on Twitter

Purple Biotech Ltd ADR Stock (PPBT) Latest News

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology

GlobeNewswire Inc.

Here's Why Purple Biotech Ltd. Sponsored ADR (PPBT) Could be Great Choice for a Bottom Fisher

Zacks Investment Research

Here's Why Purple Biotech Ltd. Sponsored ADR (PPBT) Could be Great Choice for a Bottom Fisher - Yahoo Finance

Yahoo Finance

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

GlobeNewswire Inc.

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

GlobeNewswire Inc.

Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial

GlobeNewswire Inc.

Purple Biotech Ltd ADR Stock (PPBT) Financials Data

Purple Biotech Ltd ADR (PPBT) Net Income 2024

PPBT net income (TTM) was -$19.88 million for the quarter ending December 31, 2023, a +8.25% increase year-over-year.

Purple Biotech Ltd ADR (PPBT) Cash Flow 2024

PPBT recorded a free cash flow (TTM) of -$19.93 million for the quarter ending December 31, 2023, a -17.48% decrease year-over-year.

Purple Biotech Ltd ADR (PPBT) Earnings per Share 2024

PPBT earnings per share (TTM) was -$0.91 for the quarter ending December 31, 2023, a +24.79% growth year-over-year.

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.